CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to ...

Whitecap Resources and Veren have agreed to combine their companies in $10.44 billion deal that will enlarge their Alberta oil and gas footprint. The mortgage giant Rocket Cos. has agreed to buy ...

Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its ...

Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who ...

Central to the lawsuit is the claim that the company's "optimistic forecasts" about CagriSema's effectiveness were unfounded. The suit also contends that the study's "flexible protocol," which ...

“The fourth quarter of 2024 was marked by two key announcements: the filing of patents covering, in particular, BioChaperone CagriSema—a stable combination of cagrilintide and semaglutide ...

CagriSema: Activating amylin and GLP-1 receptors CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials testing whether it can be ...

The company has grown its revenue by 18.58% over the last 5 years. NVO’s stock price fell after the CagriSema drug’s disappointing trial results. Despite strong earnings in the previous ...

Novo issued a press release on December 20, 2024, announcing the disappointing results of its "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." ...

Novo issued a press release on December 20, 2024, announcing the disappointing results of its "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." ...

The next generation of weight-loss drugs aim to help patients lose more weight even faster. CagriSema — developed by Novo Nordisk, the company behind Wegovy — is one example. In a trial last ...